Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Zrt.

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag

Adrienn Keszthelyi

Gyula Simig

Jozsef Barkoczy

Balazs Volk

Kalman Nagy

Ferenc Lorant Bartha

Zoltán Varga

Balázs Volk

Laszlo Pongo

Gábor Németh

László Szlávik

Gyorgy Krasznai

András Mravik

Mátyás Milen

Gábor Berecz

Tibor Szabo

Gabor Nemeth

József Barkóczy

Kálmán Nagy

Gyorgy Ruzsics

Gyula Lukacs

Gyula Lukács

Janos Imre

Bálint Nyulasi

Gyoergy Ruzsics

Daniel Ulej

Maria Tothne Lauritz

Andras Dancso

Gyorgyi Kovanyine Lax

Zsuzsanna Szent-Királlyi

Eva Sipos

László Pongó

Angéla Pandur

Imre Kapui

Jozsef Debreczeni

Beatrix Bali

Judit Broda

Gyoergy Clementis

Peter Slegel

Gyoergyi Kovanyine Lax

György Krasznai

Péter Slégel

Valeria Hoffmanne Fekete

Gyoergy Krasznai

Gyoergy Morovjan

Gabor Bagyinszki

Gyorgy Morovjan

József Debreczeni

Enikö Molnár

György Ruzsics

Imre Koehegyi

Imre KÖHEGYI

János Imre

Valéria HoffmannÉ Fekete

Feren Bartha

Jozsef BARKÓCZY

Tibor SzabÓ

Maria TÓTHNÉ Lauritz

Ferenc Lóránt Bartha

György MOROVJÁN

Györgyi KOVÁNYINÉ Lax

András DancsÓ

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4'-fluoro butyrophenone (X=I, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

Method for the production of lumateperone and its salts

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Inorganic salt complexes of vildagliptin

Growing community of inventors

Budapest, Hungary

Adrienn Keszthelyi